Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs DraftKings Inc (DKNG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs DraftKings Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $287.32 (market cap $39.89B), while DraftKings Inc trades at $26.35 (market cap $13.14B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 3× DraftKings Inc's market cap, and DraftKings Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | DKNG | |
|---|---|---|
Market Cap | $39.89B | $13.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $48.23 |
52-Week Low | $278.09 | $20.72 |
Enterprise Value | $38.15B | $14.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
DraftKings (DKNG) trades at $26.48, up 0.7% with neutral technical indicators. The company shows strong revenue growth, reaching $6.05B in 2025 with improving profitability, though valuation ratios remain elevated. Recent expansion into Alberta and launch of DKeX prediction platform signal growth initiatives. Analyst sentiment is bullish with 73% buy ratings and a $34.18 consensus target.
DraftKings presents growth potential through market expansion and product innovation, but faces risks from regulatory scrutiny and competitive pressures. The stock trades below analyst targets but carries high multiples, requiring sustained execution to justify valuation. Key catalysts include World Cup engagement and continued margin improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About DraftKings Inc
DraftKings Inc is a digital sports entertainment and gaming company. The company provides users with daily fantasy sports (DFS), sports betting, and iGaming opportunities and is also involved in the design & development of sports betting and casino gaming platform software for online and retail sportsbook and casino gaming products. It operates in two segments: Business-to-consumer(B2C) and Business-to-Business(B2B), of which the vast majority of its revenue comes from the B2C segment. Geographically, it derives most of its revenue from the United States.
Read more on DKNG →
